REGENXBIO (NASDAQ:RGNX - Get Free Report) will release its earnings data after the market closes on Wednesday, May 8th. Analysts expect REGENXBIO to post earnings of ($1.28) per share for the quarter. Persons interested in listening to the company's earnings conference call can do so using this link.
REGENXBIO (NASDAQ:RGNX - Get Free Report) last announced its quarterly earnings results on Tuesday, February 27th. The biotechnology company reported ($1.43) earnings per share for the quarter, missing the consensus estimate of ($1.27) by ($0.16). The company had revenue of $22.30 million during the quarter, compared to analysts' expectations of $34.01 million. REGENXBIO had a negative net margin of 291.99% and a negative return on equity of 68.18%. REGENXBIO's revenue for the quarter was down 28.8% compared to the same quarter last year. During the same quarter last year, the firm posted ($1.38) earnings per share. On average, analysts expect REGENXBIO to post $-4 EPS for the current fiscal year and $-3 EPS for the next fiscal year.
REGENXBIO Trading Up 2.7 %
Shares of NASDAQ RGNX traded up $0.44 during mid-day trading on Thursday, hitting $16.64. The company had a trading volume of 389,117 shares, compared to its average volume of 699,077. The company has a market capitalization of $816.03 million, a price-to-earnings ratio of -2.71 and a beta of 1.38. REGENXBIO has a 1 year low of $11.83 and a 1 year high of $28.80. The stock's 50-day moving average price is $19.70 and its 200-day moving average price is $17.84.
Insiders Place Their Bets
In other REGENXBIO news, CEO Kenneth T. Mills sold 15,000 shares of REGENXBIO stock in a transaction dated Wednesday, February 14th. The stock was sold at an average price of $16.76, for a total transaction of $251,400.00. Following the completion of the sale, the chief executive officer now owns 408,035 shares of the company's stock, valued at $6,838,666.60. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In other news, CEO Kenneth T. Mills sold 15,000 shares of the business's stock in a transaction dated Wednesday, February 14th. The stock was sold at an average price of $16.76, for a total value of $251,400.00. Following the completion of the sale, the chief executive officer now owns 408,035 shares of the company's stock, valued at approximately $6,838,666.60. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Steve Pakola sold 12,878 shares of the business's stock in a transaction dated Tuesday, March 5th. The shares were sold at an average price of $28.36, for a total value of $365,220.08. Following the completion of the sale, the insider now directly owns 107,192 shares of the company's stock, valued at approximately $3,039,965.12. The disclosure for this sale can be found here. Insiders sold a total of 57,878 shares of company stock valued at $1,217,370 over the last 90 days. Insiders own 13.13% of the company's stock.
Analyst Ratings Changes
RGNX has been the subject of several recent analyst reports. Chardan Capital restated a "buy" rating and set a $52.00 target price on shares of REGENXBIO in a research report on Thursday, March 7th. HC Wainwright restated a "buy" rating and set a $36.00 target price on shares of REGENXBIO in a research report on Monday, March 11th. Barclays boosted their target price on REGENXBIO from $45.00 to $55.00 and gave the stock an "overweight" rating in a research report on Thursday, March 7th. Wedbush restated a "neutral" rating and set a $21.00 target price on shares of REGENXBIO in a research report on Wednesday, February 28th. Finally, Raymond James restated an "outperform" rating and set a $45.00 target price on shares of REGENXBIO in a research report on Wednesday, February 21st. Three equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. According to data from MarketBeat, REGENXBIO currently has an average rating of "Moderate Buy" and an average target price of $38.45.
View Our Latest Stock Analysis on REGENXBIO
About REGENXBIO
(
Get Free Report)
REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.
Recommended Stories
Before you consider REGENXBIO, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and REGENXBIO wasn't on the list.
While REGENXBIO currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
